Skip to main content

Artificial Intelligence able to identify potentially life-saving antibiotics

| News

Artificial Intelligence able to identify potentially life-saving antibiotics


A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University Hospital Basel and the Basel-based Department of Biosystems Science and Engineering at the Swiss Federal Institute of Technology in Zurich will initially put their new method to the test as part of a clinical trial.

Study leader Prof. Adrian Egli with his colleague Aline Cuénod in the laboratory medicine department of the University Hospital Basel (img: USB)

Researchers from University Hospital Basel (USB) and the Department of Biosystems Science and Engineering (D-BSSE) at the Swiss Federal Institute of Technology in Zurich (ETH) in Basel are using innovative computer algorithms in the fight against antibiotic-resistant bacteria. With this new method, the researchers can identify characteristics of antibiotic resistance in germs up to 24 hours earlier. This means that it is clear sooner rather than later which antibiotics can still help patients. The cantons of Basel-Stadt and Basel-Landschaft offered financial support for this research project.

“In cases of severe infection, the time until optimal therapy can be the difference between life and death. A quick and precise diagnosis is extremely important here”, comments Professor Adrian Egli, Head of the Clinical Bacteriology department at USB and study director, in a press release.

Larger clinical study will follow

The study team linked 300,000 mass spectrometry data samples from individual bacteria from four laboratories in north-western Switzerland with the results of antibiotic resistance tests in the laboratory. “Intelligent computer algorithms look for patterns in the data that distinguish bacteria with and without resistance from one another”, explains Caroline Weis, PhD student at the D-BSSE at ETH Zurich in Basel and lead author of the study.

The researchers have published their method in the latest edition of the specialist journal “Nature Medicine”. It must now be confirmed in a larger clinical study carried out as part of everyday hospital operations. Plans are already in place for this to take place at USB.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.